2000 (10) TMI 712

X X   X X   Extracts   X X   X X

Full Text of the Document

X X   X X   Extracts   X X   X X

....llant. Shri V.K. Dahiya, JDR, for the Respondent. [Order per : Gowri Shankar, Member (T)]. -  The question for consideration in this appeal is whether the appellant was entitled to the benefit of Notification 31/88 in respect of ethopabate manufactured by it and utilised in the manufacture of 'Amprol Plus' formulation. The notification exempts bulk drugs subject to conditions specifi....

X X   X X   Extracts   X X   X X

Full Text of the Document

X X   X X   Extracts   X X   X X

....dient must itself confirm to the pharmacopoeia standard. As long as the therapeutic ingredient is a bulk drug within the meaning of the notification, therefore it cannot be said that it ceased to merit treatment as bulk drug for the purpose of notification solely because it is used an ingredient in a product that is not itself a medicament. Apart from this it has been held by the Supreme Court in ....